Maricann Group appoints CFO

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
WebinarM&A In Focus: Tech Acquisitions and the ‘New Normal’ in 2023
- 02/08/2023
- Live, Online
- 11:00 am - 12:00 pm EST
Webinar ReplaysAssessing the impact of the U.S. Government Accountability Office recommendations’ on Export Control Compliance at universities
- 01/18/2023
- On-Demand
- 60 minutes
ConferenceTPMTech
- 02/23/2023
- Hilton Long Beach Convention Center
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

3 Oct, 2017 | 18:11

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

Maricann Group Inc. appointed Scott Langille as CFO, effective Oct. 2, subject to regulatory approval.

Previously, the company's CEO Ben Ward had taken the additional role of interim CFO.

Langille was formerly CFO of Tribute Pharmaceuticals Canada Inc., which was sold to Pozen Inc. in February 2016 for $160 million to form Aralez Pharmaceuticals Inc.